title: Novel antidotes for target specific oral anticoagulants.
abstract: Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
authors.forename: Arundhati
authors.initials: A
authors.lastname: Das
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA ; Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Delong
authors.initials: D
authors.lastname: Liu